Versartis

ARAV NASDAQ
5.95
+0.13
+2.23%
休市 16:00 06/14 EDT
开盘
5.80
昨收
5.82
最高
5.95
最低
5.76
成交量
1.89万
成交均量(3M)
2.01万
52周最高
15.30
52周最低
3.070
换手率
0.17%
市值
6,709.52万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Versartis ARAV股票价格,Versartis股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
展开 >

最近浏览

名称
价格
涨跌幅